Search

Spain is one of the countries most strongly affected by the coronavirus (COVID-19) pandemic with more than 800,000 cases reported in the country as of October 5 [1]. In Madrid, the first reported c...

The COVID‐19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment that represent a vulnerable population for SARS‐CoV‐2 infection. Aggressive lymphoid neoplasms, such as diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed so as to minimize risk of SARS‐CoV‐2 infection while continuing haematological treatment. In this report, we analyse the management of front‐line therapy in 18 patients during COVID‐19 outbreak, as well as the results of the implemented measures in their outcome.

The development of inhibitors is the most serious iatrogenic complication affecting patients with haemophilia. This complication is associated with impaired vital or functional prognosis, reduced quality of life and increased cost of treatment. The reasons why some patients develop antibodies to factor replacement and others do not remain unclear. It is however clear that inhibitor development results from a complex multifactorial interaction between genetic and non-genetic risk factors. Environmental influences implicated in increasing the risk of inhibitor formation can be viewed as modifiable risk factors. Therefore, identification of the non-genetic risk factors may offer the possibility of personalising haemophilia therapy by modifying treatment strategies in high-risk patients in the critical early phase of factor VIII exposure. In this article, we review the non-genetic factors reported as well as the potential impact of danger signals and the different scores for inhibitor development risk stratification.